Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era
Introduction The Omicron BA.1 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and subsequent sub-lineages exhibit partial escape from neutralizing antibodies elicited by vaccines containing or encoding wild-type spike protein. In response to the emergence of Omicron sub-linea...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis Group
2023-12-01
|
| Col·lecció: | Expert Review of Vaccines |
| Matèries: | |
| Accés en línia: | http://dx.doi.org/10.1080/14760584.2023.2232851 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|